E. Shrayner, A. I. Khavkin, K. Nikolaychuk, M. F. Novikova, A. S. Veremenko, I. D. Levchenko, E. E. Vergunova, A. S. Tumas, P. Y. Platonova, D. R. Shaimardanova, I. A. Pak, E. Pokushalov
{"title":"The place of berberine in the treatment of metabolic syndrome","authors":"E. Shrayner, A. I. Khavkin, K. Nikolaychuk, M. F. Novikova, A. S. Veremenko, I. D. Levchenko, E. E. Vergunova, A. S. Tumas, P. Y. Platonova, D. R. Shaimardanova, I. A. Pak, E. Pokushalov","doi":"10.31146/1682-8658-ecg-218-10-95-103","DOIUrl":null,"url":null,"abstract":"The article highlights the pharmacological activity of berberine, as well as its place in the treatment of the current epidemic - metabolic syndrome. The review examines the molecular mechanisms that allows achieving anti-inflammatory, antimicrobial and antioxidant effects in detail. Berberine’s pharmacological profile makes it possible to have a positive effect on the pathway of obesity, non-alcoholic fatty liver disease, dyslipoproteinemia, the intestinal microbiome and insulin resistance. In addition, the article reviews the main pharmacokinetic parameters and side effects of chemically unmodified berberine.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"4 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Clinical Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31146/1682-8658-ecg-218-10-95-103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The article highlights the pharmacological activity of berberine, as well as its place in the treatment of the current epidemic - metabolic syndrome. The review examines the molecular mechanisms that allows achieving anti-inflammatory, antimicrobial and antioxidant effects in detail. Berberine’s pharmacological profile makes it possible to have a positive effect on the pathway of obesity, non-alcoholic fatty liver disease, dyslipoproteinemia, the intestinal microbiome and insulin resistance. In addition, the article reviews the main pharmacokinetic parameters and side effects of chemically unmodified berberine.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
